Search hospitals > Mississippi > Jackson
University Of Mississippi Medical Center
Claim this profileJackson, Mississippi 39216
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Recurrence
Conducts research for Tumors
Conducts research for Lymphoma
1030 reported clinical trials
46 medical researchers
Summary
University Of Mississippi Medical Center is a medical facility located in Jackson, Mississippi. This center is recognized for care of Cancer, Leukemia, Recurrence, Tumors, Lymphoma and other specialties. University Of Mississippi Medical Center is involved with conducting 1,030 clinical trials across 1,124 conditions. There are 46 research doctors associated with this hospital, such as Anderson (Andy) B. Collier, Betty L. Herrington, John C. Henegan, and Mark Anderson, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Leukemia
Global LeaderStage II
Stage I
Philadelphia chromosome positive
Top PIs
Anderson (Andy) B. CollierUniversity of Mississippi Medical Center7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
52 reported clinical trials
102 drugs studied
Betty L. HerringtonUniversity of Mississippi Medical Center7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
42 reported clinical trials
97 drugs studied
John C. HeneganUniversity of Mississippi Medical Center3 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
17 reported clinical trials
64 drugs studied
Mark Anderson, MDUniversity of Mississippi Medical Center5 years of reported clinical research
Studies Glioblastoma
Studies Cancer
10 reported clinical trials
24 drugs studied
Clinical Trials running at University Of Mississippi Medical Center
Breast Cancer
Lung Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Cancer
Astrocytoma
Bladder Cancer
Brain Tumor
Urothelial Carcinoma
Acute Myeloid Leukemia
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Whole Brain Radiotherapy + Stereotactic Radiosurgery
for Brain Metastasis
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread to the brain and returned in other areas of the brain after receiving stereotactic radiosurgery.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University Of Mississippi Medical Center?
University Of Mississippi Medical Center is a medical facility located in Jackson, Mississippi. This center is recognized for care of Cancer, Leukemia, Recurrence, Tumors, Lymphoma and other specialties. University Of Mississippi Medical Center is involved with conducting 1,030 clinical trials across 1,124 conditions. There are 46 research doctors associated with this hospital, such as Anderson (Andy) B. Collier, Betty L. Herrington, John C. Henegan, and Mark Anderson, MD.
Where is University Of Mississippi Medical Center located?
The University of Mississippi Medical Center is located at 2500 N State St, Jackson, MS 39216. Access is available via the stoplight at University Drive on North State Street or by taking I-55 to the Woodrow Wilson exit (98A), following signs to the new Children's Parking Garage C.
Who should I call to ask about financial aid or insurance network?
**University Of Mississippi Medical Center (UMMC) Financial and Billing Information:**
- For financial assistance, contact Patient Financial Services at 410-821-4140 or 877-632-4909 (toll-free) to check eligibility for the UMMC Financial Assistance Program or other assistance programs.
- For insurance inquiries, reach out to the Mississippi Insurance Department via their website.
- For billing questions or concerns, contact UMMC's Central Billing Office at (601) 496-9303 or (844) 838-4871.
What insurance does University Of Mississippi Medical Center accept?
The University of Mississippi Medical Center (UMMC) accepts various insurance plans, including those from UnitedHealthcare, Blue Cross Blue Shield of Mississippi, and Humana. UMMC offers a student insurance plan through UnitedHealthcare for students with at least 6 credit hours and their dependents; international students are required to have health insurance. Additionally, UMMC has in-network agreements with Blue Cross Blue Shield for all commercial health plans and with Humana for Medicare Advantage HMO and PPO plan members.
What awards or recognition has University Of Mississippi Medical Center received?
The University of Pennsylvania has been awarded the 2022 update to the research and development section.